Economic implications of evidence-based prescribing for hypertension: can better care cost less?
about
Improving the quality of health care: using international collaboration to inform guideline programmes by founding the Guidelines International Network (G-I-N)Can Aliskiren be Considered as a New Novel Drug for Hypertension?Medicaid prescription limits: policy trends and comparative impact on utilization.A review on prescribing patterns of antihypertensive drugsSorrell v. IMS Health: issues and opportunities for informaticiansA blueprint for pharmacy benefit managers to increase valuePotential Savings from an Evidence-Based Consumer-Oriented Public Education Campaign on Prescription DrugsEvaluation of prescribing patterns in a German network of CAM physicians for the treatment of patients with hypertension: a prospective observational study.Laboratory testing in newly treated elderly hypertensive patients without co-morbidities: a population-based cohort studyThe role of ethics committees and ethics consultation in allocation decisions: a 4-stage processMultiple drug cost containment policies in Michigan's Medicaid program saved money overall, although some increased costsChange in antihypertensive drug prescribing after guideline implementation: a controlled before and after study.Evaluation of thiazide diuretic use as preferred therapy in uncomplicated essential hypertension patientsAn evaluation of a clinical pharmacy-directed intervention on blood pressure control.Prescribing of Antihypertensive Agents in Public Primary Care Clinics - is it in Accordance with Current Evidence?Study protocol of EMPOWER participatory action research (EMPOWER-PAR): a pragmatic cluster randomised controlled trial of multifaceted chronic disease management strategies to improve diabetes and hypertension outcomes in primary care.Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses AssociationPerindopril: the evidence of its therapeutic impact in hypertension.Anti hypertensive prescribing patterns and cost analysis for primary hypertension: a retrospective study.Economic evaluation for first-line anti-hypertensive medicines: applications for the Philippines.Marketing, media, wishful thinking, and conflicts of interest: inflating the value of new medical technology.Toward excellence in health care: a call for the Saudi Center for Health Excellence.Variability in drug formularies and implications in decision support.Sources of regional variation in Medicare Part D drug spending.Aliskiren in hypertension: evidence for its potential therapeutic valueCurrent trends in treatment of hypertension in Karachi and cost minimization possibilities.Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution.Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication useA randomized study of how physicians interpret research funding disclosures.Prevention of cardiovascular events by treating hypertension in older adults: an evidence-based approach.Assessing the impact of drug use on hospital costs.Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial.Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.Initial antihypertensive prescriptions, switching patterns and adherence among insured patients in Hawai'iImpact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.Patients' perceptions of generic medications.Whom do older adults trust most to provide information about prescription drugs?Self-Reported Rationing Behavior Among US Physicians: A National Survey.Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study.Cost implications of new evidence on prevention of cardiovascular disease.
P2860
Q24680011-08B0D99D-FC86-4C6D-ABD6-16B60F1F353DQ26775106-96079F71-8D5F-4997-B2E1-61A3B6B7B096Q27306989-6118C8B3-6ACC-473B-AD3E-BA94A16F7AC9Q28088649-AED98C14-88C5-43F1-8281-21EF5F6F2260Q28709485-B4254DE7-3E28-4D87-99A5-F8381D17DFBFQ28766235-680294BF-F61B-4E04-A391-9C40649BBA86Q29393270-1FA9A29A-6F30-4FD8-BC0B-4109B1A30FC9Q33517915-A180BC6C-9BA1-4209-840E-6CBA0094D2FBQ33572877-8D22D05F-97CB-4744-834F-660A2BFD3CBAQ33655955-9E0FBA5D-E491-47AA-8B0E-59AE208570EBQ33988439-AC48317F-E084-4274-9EA4-F2615AAA5683Q33995134-0D57CD78-FB2E-48B4-B843-8613048B4119Q34134078-1960D35E-A026-43F9-97C3-210E3819DEDEQ34145117-FBC664C2-CEF0-4F4F-B0A1-E7067C4BC82BQ34220716-AE16746D-25CB-457F-8975-D82C627723D0Q34241759-2E70A794-AA66-4967-8E85-4B94ED94833DQ34338939-F33E7795-9D1E-457D-A29F-C345330213CEQ34450527-4DB472FE-2979-424C-A605-C8E20A9D55B2Q34479742-928749EE-A3DC-4EC3-87F4-F7B8C358432DQ34507583-E39F3E8A-4847-4A83-9B12-CACF3D50F031Q34555565-B5ABBFBB-15C2-4170-B457-38AC7B507CC0Q35610959-AE7B0DC5-EF19-4DF9-AC92-45271262F6A8Q35625221-1FD75249-070A-4069-90BB-276BA670D4FBQ35773656-3FBFEA28-D93E-4B0F-86C5-FBFA5ACC5865Q35876368-5FBB442D-D744-4A33-897C-BF02EC0A28D1Q36270041-2F0D9FB6-66DE-41E3-BA50-A0274CA573EDQ36388093-3BDB5EAB-50F1-481E-B1B9-263D515D0F39Q36416773-BAD50694-5324-4885-B7A7-42E723667F3FQ36513939-C4C562F4-D502-4993-9BBA-556D9E3F31E9Q37104525-A24674EC-43BB-42D8-8025-BF04C2D2A588Q37159754-7B4C0BC4-5772-445C-B787-6A56FCB77C03Q37196480-49E682E8-B3D8-4EF0-98E3-54808077E9A9Q37269872-6B83F46D-82B7-498F-97D2-297D286FAA63Q37351708-BC0E59F4-8350-43FF-A2F5-5A9DC2E500F9Q37352239-0CB7822E-8F3E-45DA-9AAE-ED04F50FB272Q37357331-26CC56A9-7314-4AC0-BA42-EF16D90B0A0CQ37435060-C579C0E8-DE8B-4129-987F-1B420615312AQ37459166-EDC39094-A856-46DB-9BEA-BC8F337C7C4DQ37471385-ADE7F926-4CE0-43AB-BF63-8ED41EF50D4CQ37609391-E9D30033-6323-4042-B5B8-5D7DA756D98C
P2860
Economic implications of evidence-based prescribing for hypertension: can better care cost less?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Economic implications of evide ...... on: can better care cost less?
@en
Economic implications of evide ...... on: can better care cost less?
@nl
type
label
Economic implications of evide ...... on: can better care cost less?
@en
Economic implications of evide ...... on: can better care cost less?
@nl
prefLabel
Economic implications of evide ...... on: can better care cost less?
@en
Economic implications of evide ...... on: can better care cost less?
@nl
P356
P1476
Economic implications of evide ...... on: can better care cost less?
@en
P2093
Jerry Avorn
Michael A Fischer
P304
P356
10.1001/JAMA.291.15.1850
P407
P577
2004-04-01T00:00:00Z